Pontificia Universidad Católica de Chile

Chilean RSV Vaccine Advances to Phase 2 Clinical Trials in Europe, Targeting Elderly Population

- A groundbreaking RSV vaccine developed by Chilean researchers at UC Chile has received approval for Phase 2 clinical trials in Europe, focusing on adults over 60 years old. - The vaccine demonstrated promising safety and efficacy results in preclinical studies and Phase 1 trials, marking a significant milestone for Chilean scientific research in global healthcare. - RSV causes approximately 3.4 million hospitalizations worldwide annually and affects nearly 5% of infants and children under 5 with acute lower respiratory infections.